All In Biotech

Drug Trial Radar · NCT03779113

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

69

Actual

Start

Sep 26, 2019

Primary completion

Feb 26, 2025

Study completion Feb 26, 2025

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

Conditions

  • Non Hodgkin Lymphoma

Interventions

  • HMPL-523Drug

    Oral HMPL-523

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (each cycle was 28 days)
  2. Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment DiscontinuationTime frame: From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 29 months
  3. Dose Escalation Stage: Recommended Phase 2 Dose of HMPL-523Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (each cycle was 28 days)
  4. Dose Expansion Stage: Objective Response Rate (ORR)Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
  5. Dose Expansion Stage: Complete Response RateTime frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
  6. Dose Expansion Stage: Clinical Benefit Rate (CBR)Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
  7. Dose Expansion Stage: Duration of Response (DOR)Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
  8. Dose Expansion Stage: Time to Response (TTR)Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
  9. Dose Expansion Stage: Progression-Free Survival (PFS)Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months

Locations

32 sites in 7 countries. Site status is shown where the registry gives one.

  • Pacific Cancer Medical Center, Inc.

    Anaheim, California

  • Innovative Clinical Research Institute

    Downey, California

  • Ventura County Hematology-Oncology Specialists

    Oxnard, California

  • Summit Medical Group

    Florham Park, New Jersey

  • Clinical Research Alliance

    New Hyde Park, New York

  • Leo Jenkins Cancer Center/ECU School of Medicine

    Greenville, North Carolina

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Renovatio Clinical

    The Woodlands, Texas

  • Aarhus University Hospital

    Aarhus, Denmark

  • Helsingin yliopistollinen keskussairaala

    Helsinki, Finland

  • Tampereen yliopistollinen sairaala

    Tampere, Finland

  • CHU Clermont Ferrand - Hôpital d'Estaing

    Clermont-Ferrand, France

  • Hôpital Henri Mondor

    Créteil, France

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, France

  • CHU Poitiers - Hôpital la Milétrie

    Poitiers, France

  • Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)

    Monza, Italy

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)

    Bergamo, Bergamo, Italy

  • Ospedale San Raffaele

    Milan, Milano, Italy

  • KO-MED Centra Kliniczne

    Biała Podlaska, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Nasz Lekarz Przychodnie Medyczne

    Torun, Poland

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego

    Wroclaw, Poland

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • ICO Badalona - Hospital Universitari Germans Trias i Pujol

    Barcelona, Spain

  • Institut Català d'Oncologia

    Barcelona, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Universitario Infanta Leonor

    Madrid, Spain

  • Hospital Universitario Quironsalud Madrid

    Madrid, Spain

  • MD Anderson Cancer Centre

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.